Measurable residual disease in the treatment of chronic lymphocytic leukemia

被引：7

作者：

Uchiyama, Takayoshi ^{[1
]}

Yokoyama, Aki ^{[1
]}

Aoki, Sadao ^{[1
]}

机构：

[1] Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Dept Pathophysiol, Niigata, Japan

来源：

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2020年 / 60卷 / 04期

关键词：

measurable residual disease; chronic lymphocytic leukemia; multicolor flow cytometry; ibrutinib; venetoclax; CIRCULATING TUMOR DNA; MANTLE CELL LYMPHOMA; DIGITAL-DROPLET-PCR; FLOW-CYTOMETRY; RQ-PCR; DIFFERENTIAL-DIAGNOSIS; GENE REARRANGEMENTS; PERIPHERAL-BLOOD; CLL; QUANTIFICATION;

D O I：

10.3960/jslrt.20014

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in several clinical trials on CLL using flow cytometry, real-time quantitative PCR (RQ-PCR) with allele-specific oligonucleotide (ASO) primers, and high-throughput sequencing. MRD assessment is useful to predict the treatment outcomes in the context of chemotherapy and treatment with novel drugs such as venetoclax. In this review, we discuss major techniques for MRD assessment, data from relevant clinical trials, and the future of MRD assessment in CLL treatment.

引用

页码：138 / 145

页数：8

共 58 条

[1] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study [J].

Ahn, Inhye E. ;

Farooqui, Mohammed Z. H. ;

Tian, Xin ;

Valdez, Janet ;

Sun, Clare ;

Soto, Susan ;

Lotter, Jennifer ;

Housel, Stephanie ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance M. ;

Maric, Irina ;

Calvo, Katherine R. ;

Nierman, Pia ;

Hughes, Thomas E. ;

Saba, Nakhle S. ;

Marti, Gerald E. ;

Pittaluga, Stefania ;

Herman, Sarah E. M. ;

Niemann, Carsten U. ;

Pedersen, Lone B. ;

Geisler, Christian H. ;

Childs, Richard ;

Aue, Georg ;

Wiestner, Adrian .

BLOOD, 2018, 131 (21) :2357-2366

[2] Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model [J].

Baumann, Tycho ;

Delgado, Julio ;

Santacruz, Rodrigo ;

Martinez-Trillos, Alejandra ;

Royo, Cristina ;

Navarro, Alba ;

Pinyol, Magda ;

Rozman, Mara ;

Pereira, Arturo ;

Villamor, Neus ;

Aymerich, Marta ;

Lopez, Cristina ;

Carrio, Anna ;

Montserrat, Emili .

HAEMATOLOGICA, 2014, 99 (10) :1599-1604

[3] SIGNIFICANT ENLARGEMENT OF A SPECIFIC SUBSET OF CD3+CD8+ PERIPHERAL-BLOOD LEUKOCYTES MEDIATING CYTOTOXIC T-LYMPHOCYTE ACTIVITY DURING HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].

BENSUSSAN, A ;

RABIAN, C ;

SCHIAVON, V ;

BENGOUFA, D ;

LECA, G ;

BOUMSELL, L .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (20) :9427-9430

[4] Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis [J].

Boettcher, S. ;

Stilgenbauer, S. ;

Busch, R. ;

Brueggemann, M. ;

Raff, T. ;

Pott, C. ;

Fischer, K. ;

Fingerle-Rowson, G. ;

Doehner, H. ;

Hallek, M. ;

Kneba, M. ;

Ritgen, M. .

LEUKEMIA, 2009, 23 (11) :2007-2017

[5] The Role of Minimal Residual Disease Measurements in the Therapy for CLL Is It Ready for Prime Time? [J].

Boettcher, Sebastian ;

Hallek, Michael ;

Ritgen, Matthias ;

Kneba, Michael .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (02) :267-+

[6] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Fischer, Kirsten ;

Stilgenbauer, Stephan ;

Busch, Raymonde M. ;

Fingerle-Rowson, Guenter ;

Fink, Anna Maria ;

Buehler, Andreas ;

Zenz, Thorsten ;

Wenger, Michael Karl ;

Mendila, Myriam ;

Wendtner, Clemens-Martin ;

Eichhorst, Barbara F. ;

Doehner, Hartmut ;

Hallek, Michael J. ;

Kneba, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :980-988

[7] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation [J].

Böttcher, S ;

Ritgen, M ;

Pott, C ;

Brüggemann, M ;

Raff, T ;

Stilgenbauer, S ;

Döhner, H ;

Dreger, P ;

Kneba, M .

LEUKEMIA, 2004, 18 (10) :1637-1645

[8] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[9] Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma [J].

Cavalli, Marzia ;

De Novi, Lucia Anna ;

Della Starza, Irene ;

Cappelli, Luca Vincenzo ;

Nunes, Vittorio ;

Pulsoni, Alessandro ;

Del Giudice, Ilaria ;

Guarini, Anna ;

Foa, Robin .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (04) :588-596

[10] Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study [J].

Chanan-Khan, Asher ;

Cramer, Paula ;

Demirkan, Fatih ;

Fraser, Graeme ;

Silva, Rodrigo Santucci ;

Grosicki, Sebastian ;

Pristupa, Aleksander ;

Janssens, Ann ;

Mayer, Jiri ;

Bartlett, Nancy L. ;

Dilhuydy, Marie-Sarah ;

Pylypenko, Halyna ;

Loscertales, Javier ;

Avigdor, Abraham ;

Rule, Simon ;

Villa, Diego ;

Samoilova, Olga ;

Panagiotidis, Panagiots ;

Goy, Andre ;

Mato, Anthony ;

Pavlovsky, Miguel A. ;

Karlsson, Claes ;

Mahler, Michelle ;

Salman, Mariya ;

Sun, Steven ;

Phelps, Charles ;

Balasubramanian, Sriram ;

Howes, Angela ;

Hallek, Michael ;

Assouline, S. ;

Bence-Bruckler, I. ;

Buckstein, R. ;

Fraser, G. ;

Larratt, L. ;

Minuk, L. ;

Villa, D. ;

Angevine, A. ;

Bartlett, N. ;

Bixby, D. ;

Caimi, P. ;

Chanan-Khan, A. ;

Craig, M. ;

Forero-Torres, A. ;

Ganguly, S. ;

Goy, A. ;

Heffner, L. ;

Hermann, R. ;

Lansigan, F. ;

Leis, J. ;

Letzer, J. .

LANCET ONCOLOGY, 2016, 17 (02) :200-211

← 1 2 3 4 5 6 →